Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166393 · ClinicalTrials.gov registry record · Phase 2
Valproic AcId for Traumatic BRAin INjury Trial
A Phase 2 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT07166393: Clinical Trial Phase 2 study, sponsored by Northwestern University.
NCT07166393 is a Phase 2 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 432 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (225% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166393, a Phase 2 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose
Primary Outcome
Scoring values range from 1 to 8 with higher scores representing a better outcome. 1 indicates death, 2 indicates a vegetative state, 3 or 4 indicates severe disability, 5 or 6 indicates moderate disability, and 7 or 8 indicates good recovery.
Interventions
- DRUG Valproic Acid (VPA)
- OTHER Standard of care treatment + normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2026-05 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What is known before NCT07166393 opens enrollment
NCT07166393 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (225% higher).
The record links to 0 conditions, and to 2 interventions - of which Valproic Acid (VPA) is the first listed.
NCT07166393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07166393 about?
NCT07166393 is a clinical study titled "Valproic AcId for Traumatic BRAin INjury Trial". The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal sali...
What is the current status of trial NCT07166393?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2026-05. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07166393?
The interventions under investigation include: Valproic Acid (VPA) (DRUG), Standard of care treatment + normal saline (OTHER).
Who is sponsoring clinical trial NCT07166393?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07166393's enrollment target sits among peer trials
432 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia